[Evaluation of @entity8933 in the treatment of XXXX ].

@entity1 @entity1997 @entity796 @entity390 @entity6283 @entity55 @entity8934 @entity2260 @entity327 @entity391 @entity344 @entity3274 @entity1729 @entity11592 @entity8933
@entity8933 ( @entity8934 ) was used for 33 @entity1 with @entity1729 ; 22 @entity1 with @entity55 , 3 @entity1 with @entity1997 , 4 @entity1 with @entity11592 and 4 @entity1 with acute exacerbation of bronchiectasia. Clinical effects of CZX were evaluated in 33 @entity1 ; excellent in 16 and good in 14 @entity1 . The efficacy rate was 91%. Bacteriological effects of CZX were prominent in 7 @entity1 infected with @entity2260 , @entity327 , @entity3274 and Citrobacter, but not in a @entity1 infected with @entity796 . The elimination rate was 92% (12/13). As the side effects, exanthema in 1 @entity1 and @entity344 ( @entity390 and @entity391 ) in 1 @entity1 were observed. However, they improved without any treatment by cessation of CZX use. Abnormal laboratory findings were observed in 2 @entity1 with elevated GOT and/or @entity6283 . They normalized after cessation of drug. The usefulness of CZX was 82% (27/33). Therefore, CZX is a very useful drug and its effects are promising in clinical management of @entity1729 .
